[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640840":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":62,"collaborators":25,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":25,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotic Desulfovibrio piger","EXPERIMENTAL","Probiotic bacteria D. piger (10\\^9 colony forming units (CFU) in 10ml PBS containing 10% glycerol and 10% maltodextrin)",[13],"Dietary Supplement: Probiotic dietary supplement",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","placebo (10ml PBS containing 10% glycerol and 10% maltodextrin)",[19],"Dietary Supplement: Placebo",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Probiotic dietary supplement",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo (10ml PBS containing 10% glycerol and 10% maltodextrin)",[15],[30],{"name":31,"affiliation":32,"role":33},"Max Nieuwdorp, Prof. Dr.","Amsterdam UMC","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","+31 20-5669111","m.nieuwdorp@amsterdamumc.nl",[40,55],{"facility":41,"status":42,"city":43,"state":25,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Diabeter Centrum Amsterdam","RECRUITING","Amsterdam","1066 EC","Netherlands","NL",{"type":48,"coordinates":49},"Point",[50,51],4.88969,52.37403,{"lat":51,"lon":50},[54],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},{"facility":32,"status":42,"city":43,"state":25,"zip":56,"country":45,"countryCode":46,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"1105 AZ",{"type":48,"coordinates":58},[50,51],{"lat":51,"lon":50},[61],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},{"type":33,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Max Nieuwdorp","Principal Investigator (prof dr)","100640840","effect-of-4-weeks-of-oral-probiotic-desulfovibrio-piger-supplementation-on-immunological-and-metabolic-parameters-in-individuals-with-longstanding-type-1-diabetes-100640840",false,"NCT07585994","Effect of 4 Weeks of Oral Probiotic Desulfovibrio Piger Supplementation on Immunological and Metabolic Parameters in Individuals With Longstanding Type 1 Diabetes","PROSPER","Inclusion Criteria:\n\n* Males or females, age \\>18 years\n* A diagnosis of type 1 diabetes, with duration of more than 5 years, with minimally one of antiGAD65, IA2, ZnT8 autoantibodies present assessed at diagnosis or routine visits at Diabeter Centrum.\n* Evidence of remaining residual beta cell function with detectable UCPCR (more than 0.01 nmol\u002Fmmol C-peptide\u002Fcreatinine ratio) and or fasting plasma C-peptide more than 0.2 mmol\u002FL.\n* BMI 18-30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Use of antibiotics or proton-pump inhibitors within the last three months before screening or during study period\n* Use of other probiotic supplementation within the last month before screening or during study period\n* A history of cholecystectomy\n* Overt untreated gastrointestinal disease, inflammatory bowel disease or abnormal bowel habits\n* Absence of a large bowel (ie colostomy)\n* Evidence for comprised immunity (HIV infection, chemotherapy, other autoimmune diseases, systemic anti-inflammatory therapy)\n* History of cardiovascular disaeses (CVD) events\n* Hepatic enzymes\\>2.5 higher than the upper limit of normal range, determined during MARVEL visits\u002Froutine visits\n* Kidney failure (eGFR \\\u003C15ml.min\u002F1.73m2), dialysis, kidney transplantation,\n* Inability or unwillingness to donate feces or urine.\n* Smoking or illicit drug use (e.g. MDMA\u002Famphetamine\u002Fcocaine\u002Fheroin\u002FGHB) in the past three months or use during the study period.\n* Alcohol abuse (equal or above 21 units per week)\n* Inability or unwillingness to provide informed consent.","ALL","18 Years",{"count":75,"type":76},20,"ESTIMATED","INTERVENTIONAL",[79],"NA","The goal is to establish the effect of oral probiotic Desulfovibrio piger (D. piger) supplementation on immunological and metabolic parameters in individuals with longstanding type 1 diabetes with residual beta cell function. The investigators will perform a double-blind, randomized, placebo-controlled trial in 2x10 participants to measure effects of D. piger on parameters of systemic and intestinal inflammation and residual beta cell function.",[82],"Type 1 Diabetes Mellitus",[84,85,86,87,88],"type 1 diabetes mellitus","gut microbiome","probiotics","immunological parameters","residual beta cell function","2026-05-10",{"date":91,"type":92},"2026-05-14","ACTUAL",{"date":94,"type":76},"2026-05",{"date":96,"type":76},"2028-05",{"name":5,"class":6},2]